Pemetrexed (Alimta)
Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
Translational Cancer Research 2023 August 31 [Link] Martine Wyrich, Henning Ohlig, Michael Wessolly, Elena Mairinger, Julia Steinborn, Luka Brcic, Balazs Hegedus, Thomas Hager, Kristina Greimelmaier, Jeremias Wohlschlaeger, Fabian D Mairinger, Sabrina Borchert Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin…
Read MoreCAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
Cell Death Discovery 2023 July 21 [Link] Sivasundaram Karnan, Akinobu Ota, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Muhammad Nazmul Hasan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, Hideaki Ito, Yoshifumi Kaneko, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa Abstract Malignant mesothelioma (MMe) is a rare but aggressive malignancy. Although the molecular…
Read MoreSETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53
British Journal of Cancer 2023 June 27 [Link] Mengting Xu, Yuqing Tu, Wenhui Bi, Meijun Z Lundberg, Isabella Klooster, Jonathan A Fletcher, Wen-Bin Ou Abstract Background: Mutational inactivation of the SETDB1 histone methyltransferase is found in a subset of mesothelioma, particularly in cases with near-haploidy and TP53 mutations. However, the tumourigenic consequences of SETDB1 inactivation…
Read MoreIndolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins
Frontiers in Oncology 2023 May 25 [Link] Sophia Steinlein, Frank Essmann, Amanda Franceschini Ghilardi, Heike Horn, Julia Schüler, Angelika Hausser, Lijun Sun, German Ott, Claudia Kalla Abstract Introduction: Malignant pleural mesothelioma (MPM) is a neoplasm with dismal prognosis and notorious resistance to the standard therapeutics cisplatin and pemetrexed. Chalcone derivatives are efficacious anti-cancer agents with…
Read MoreCombination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Lung Cancer 2023 June [Link] Akio Tada, Toshiyuki Minami, Hidemi Kitai, Yoko Higashiguchi, Mayuko Tokuda, Tomoki Higashiyama, Yoshiki Negi, Daisuke Horio, Yasuhiro Nakajima, Taiichiro Otsuki, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Kazuhiro Kitajima, Masaki Ohmuraya, Kozo Kuribayashi, Takashi Kijima Abstract Malignant pleural mesothelioma (MPM) is an asbestos-related fatal malignant neoplasm. Although there has been no…
Read MorePhase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Journal of Clinical Oncology 2023 April 20 [Link] Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti Abstract Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months,…
Read MoreBenefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
Cancers 2023 February 28 [Link] Mhd Ouis Al Khatib, Giulia Pinton, Laura Moro, Chiara Porta Abstract Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer that is mainly associated with prior exposure to asbestos fibers. Despite being a rare cancer, its global rate is increasing and the prognosis remains extremely poor. Over the last two…
Read MoreLong-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
Case Reports in Medicine 2023 February 28 [Link] Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo Abstract A 76-year-old woman presented with lower abdominal pain and nausea and was referred to the gastroenterology department in our institution. Previous contrast-enhanced computed tomography (CE-CT) for…
Read MoreNovel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
Lung Cancer 2023 April [Link] Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M Haikala, Olli Kallioniemi, Mikko I Mäyränpää, Ilkka Ilonen Abstract Objectives: Pleural mesothelioma (PM) is an aggressive malignancy with limited treatment options. The first-line therapy has remained unchanged for two decades and consists of pemetrexed in combination…
Read MoreThe Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
Asian Pacific Journal of Cancer Prevention 2023 January 1 [Link] Nagwa Ismail Wahba, Ola Khorshid, Fatma Abo Elkasem, Abeer Bahnassy, Rabab Gaafer Abstract Background: A rare yet severe neoplasia called malignant pleural mesothelioma (MPM) typically manifests itself in advanced stages. Despite some improvements in the treatment of patients with MPM, this malignancy continues to have…
Read More